Regulator DCGI cleared the use for India’s first Covid-19 test Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) named after Satyajit Ray’s character ‘Feluda’. The paper-strip COVID-19 test is developed by the combined effort of Tata Groups and CSIR-IGIB (Institute of Genomics and Integrative Biology).
The test shows the result of patients with novel coronavirus within minutes. As per a joint statement by Tata Sons Private Limited and the Ministry of Science & Technology, the indigenous test is not only cost-effective but also, 98% accurate in detecting the novel coronavirus and 96% sensitivity.
It is developed by using indigenous genome editing technology to defect the virus. The test by ‘Feluda’ can cost Rs. 500, which is comparatively lower than tests done by other Covid-19 kits.
The joint statement reads: “The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19. This marks a significant achievement for the Indian scientific community, moving from R&D to a high-accuracy, scalable, and reliable test in less than 100 days. The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use. Moreover, CRISPR is a futuristic technology that can also be configured for the detection of multiple other pathogens in the future”.
The ‘Feluda’ test is made in India product that is safe, reliable, affordable, and accessible. The CEO of TATA Medical and Diagnostic Ltd, Girish Krishnamurthy said,
“The approval for the Tata CRISPR test for COVID-19 will give a boost to the country’s efforts in fighting the global pandemic.”
He further adds, “The commercialization of the Tata CRISPR test reflects the tremendous R&D talent in the country, which can collaborate to transform India’s contributions to the global healthcare and scientific research world.”